ABE8 Base Editor for G6PC Mutation Correction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current genome editing technologies, such as those using the CRISPR system, are inefficient for correcting point mutations in genetic diseases like Glycogen Storage Disease Type 1a (GSD1a), often resulting in random insertions or deletions (indels) rather than precise corrections, which is not suitable for addressing the underlying genetic defects.
Innovation Solution
The use of a programmable nucleobase editor, specifically an Adenosine Deaminase Base Editor 8 (ABE8), to precisely correct deleterious mutations in the G6PC gene associated with GSD1a by converting A•T to G•C, thereby addressing the inefficiencies of existing genome editing methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If CRISPR system is used to correct point mutations, then gene correction can be achieved, but random insertions or deletions (indels) are introduced at the target locus
Solution Approach 1:
The patent replaces the mechanical DNA breaking mechanism of CRISPR-Cas9 with a chemical base editing approach. The base editor uses a deaminase enzyme to chemically convert cytosine to uracil in DNA, which is then repaired by cellular enzymes to produce the desired point mutation without creating double-strand breaks or random indels.
Solution Approach 2:
The patent changes the fundamental mechanism of genetic editing from physical DNA cleavage to chemical base modification. By using deaminase enzymes to convert bases chemically rather than breaking and rejoining DNA strands, the system achieves precise point mutations without the harmful side effects of CRISPR-induced indels.
2Productivity
If CRISPR system is used for genome editing, then gene correction is possible, but the efficiency is low and produces many undesired products
Solution Approach 1:
The patent substitutes the mechanical DNA break-and-repair mechanism with a chemical base conversion approach. This replacement eliminates the need for DNA double-strand breaks, thereby improving efficiency and reducing the generation of undesired products such as indels and translocations.
Solution Approach 2:
The patent converts the cellular DNA repair process, which normally produces random indels after CRISPR cutting, into a beneficial precise repair mechanism. By using base editing, the cellular repair system is guided to produce only the desired point mutation through enzymatic conversion rather than random rejoining.
3Manufacturing precision
If conventional genome editing is used to treat GSD1a, then treatment approach is established, but the underlying genetic defect cannot be precisely corrected
Solution Approach 1:
The patent replaces complex mechanical DNA manipulation systems with a simpler chemical enzyme-based approach. The base editor uses deaminase enzymes that chemically convert cytosine to uracil, providing a more feasible and precise method for correcting the specific point mutations in GSD1a without the complexity of CRISPR delivery and control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for precise correction of pathogenic amino acids in the G6PC gene, potentially offering a more effective treatment for GSD1a by reducing undesired genetic alterations and improving treatment outcomes.
Implementation Method 1
an adenosine (A) base editor (ABE) (e.g., ABE8) to precisely correct a single nucleotide polymorphism in the endogenous G6PC gene
Data Source
AI summary
The invention provides compositions comprising novel adenosine base editors (e.g., ABE8) that have increased efficiency and methods of using base editors comprising adenosine deaminase variants for altering mutations associated with Glycogen Storage Disease Type 1a (GSD1a).